Efficacy and Safety of Transcranial dIrect Current stiMulation (tDCS) in Progressive Supranuclear Palsy (PSP) (STIM-PSP)

Overview

This is a double-blind, randomized, sham-controlled clinical trial that aim to verify the safety and the efficacy of anodal transcranial direct current stimulation (tDCS) on cognitive and motor symptoms in Progressive Supranuclear Palsy (PSP) over the left dorsolateral prefrontal cortex (dlPFC).

Full Title of Study: “Efficacy and Safety of Transcranial dIrect Current stiMulation (tDCS) on Motor and Cognitive Symptoms in Progressive Supranuclear Palsy (PSP) (STIM-PSP)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Outcomes Assessor)
  • Study Primary Completion Date: May 11, 2022

Detailed Description

Progressive Supranuclear Palsy (PSP) is a rapidly progressive neurodegenerative disease characterized by deposition of tau and motor, cognitive and behavioral symptoms. Since no effective treatment is available, non-invasive brain stimulation techniques, such as tDCS, could be a valid complementary therapeutic approach. The tDCS modulates the spontaneous activity of the neural network by applying a direct current flow on the cortical brain areas (anodic or cathodic stimulation). Despite its efficacy in psychiatric disorders, the therapeutic use of tDCS in neurodegenerative diseases requires more systematic studies. The aim of this study is to verify the safety and efficacy of tDCS in PSP on motor, cognitive and behavioral symptoms.

Interventions

  • Device: Anodal transcranial direct current stimulation (a-tDCS)
    • tDCS is delivered by a battery-driven constant current stimulator thought a pair of saline soaked surface sponge electrodes. The active electrode (anode) is placed on the scalp over the left dlPFC (F3) according to the 10 to 20 international electroencephalogram coordinates) and the cathode is placed over the right deltoid muscle. During real stimulation a constant current of 2mA (milli Ampere) is applied for 20 minutes.
  • Device: Sham Condition
    • For the sham condition the electrode placement is the same of active tDCS but the electric current is ramped down 5 seconds after the beginning of the stimulation.

Arms, Groups and Cohorts

  • Experimental: Real tDCS group
    • Participants receive anodal tDCS on the left dlPFC for 5 days/week for 2 weeks
  • Sham Comparator: Sham group
    • Participants receive sham stimulation on the left dlPFC for 5 days/week for 2 weeks

Clinical Trial Outcome Measures

Primary Measures

  • Change from baseline to 3-month follow up in verbal fluency task
    • Time Frame: Baseline (T0); At 3-month (T3)
    • fluency in verbal names

Secondary Measures

  • Change from baseline to 3-month follow in motor symptoms as assessed with sensor recordings (OPAL system)
    • Time Frame: Baseline (T0); At 3-month (T3)
    • movements recorded with digital sensors (gait and other tasks)
  • Change from baseline to 3-month follow up in cognitive symptoms as assessed with Montreal Cognitive Assessment (MOCA)
    • Time Frame: Baseline (T0); At 3-month (T3)
    • Cognitive status assessed with Montreal Cognitive Assessment (MOCA). The cut off is 15,5. The minimum value is 0 and the maximum is 30. Higher scores mean a better outcome.
  • Change from baseline to 3-month follow up in caregiver distress as assessed with Neuropshychiatric Inventory (NPI)
    • Time Frame: Baseline (T0); At 3-month (T3)
    • depression symptoms, apathy, neuropsychiatric symptoms assessed with Neuropshychiatric Inventory (NPI) . The minimum value of distress is 0 and the maximum is 5. Higher scores mean a worse outcome.
  • Change from baseline to 3-month follow up in executive function as assessed with Frontal Assessment Battery (FAB)
    • Time Frame: Baseline (T0); At 3-month (T3)
    • Executive function assessed with Frontal Assessment Battery (FAB). The cut off is 13,4. The minimum value is 0 and the maximum is 18. Higher scores mean a better outcome.
  • Change from baseline to 3-month follow up in attention as assessed with Frontal Assessment Battery (FAB)
    • Time Frame: Baseline (T0); At 3-month (T3)
    • Attention assessed with Frontal Assessment Battery (FAB). The cut off is 13,4. The minimum value is 0 and the maximum is 18. Higher scores mean a better outcome.
  • Change from baseline to 3-month follow up in caregiver distress as assessed with Zarit Carer Burden Burden Interview (ZBI)
    • Time Frame: Baseline (T0); At 3-month (T3)
    • Caregiver distress assessed with Zarit Carer Burden Burden Interview (ZBI). The minimum value is 0 and the maximum is 88. The cut off is 46. Higher scores mean a worse outcome.

Participating in This Clinical Trial

Inclusion Criteria

  • Diagnosis of PSP according with Movement Disorder Society (MDS) criteria (Hoglinger et al., 2017); – Age > 40 and < 89 years; – Presence of a caregiver supportive the patient for all study procedure; – Ability to walk for at least 5 steps either independently or with a minimum support (another patients holding patient's arm or with a walker) Exclusion Criteria:

  • Presence of electrical stimulators (for example, pacemaker, Deep Brain Stimulation, DBS) – Difficult in understanding Italian language – Presence of severe sensory deficits (for example, visual or hearing impairments) – Education level <5 years – History of drug abuse – History of severe psychiatric disorders – History of transient ischemic attacks – Cortical or sub-cortical vascular lesions – Seizures or severe heart problems and previous neurosurgical operations – Absence of subjective cognitive deficits – MMSE (Mini-Mental State Examination) score <20 – Left-handedness

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: 89 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Salerno
  • Provider of Information About this Clinical Study
    • Principal Investigator: Marina Picillo, Clinical Professor – University of Salerno

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.